(Reuters) - The addition of Tykerb to standard chemotherapy treatment
failed to help most breast cancer patients, the researchers
told a meeting of the American Society of Clinical Oncology.
However, it did increase survival in those patients who
were HER2-positive, a type of breast cancer that spreads more
quickly and accounts for a quarter of cases, they said.
Read more at Reuters.com Government Filings News
failed to help most breast cancer patients, the researchers
told a meeting of the American Society of Clinical Oncology.
However, it did increase survival in those patients who
were HER2-positive, a type of breast cancer that spreads more
quickly and accounts for a quarter of cases, they said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment